CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
sFilm-FS +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04660721
NCT04660721Phase 2Completed

A Phase I/II, Randomized, Prospective, Controlled, Multi-center, Open-label, Two-arm Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Liver Bleeding During Elective Surgery

Sealantium Medical Ltd.·interventional·Posted Dec 9, 2020·Updated Mar 21, 2025

In Brief

A Phase 2 clinical trial evaluating sFilm-FS and TACHOSIL® for Hemostasis and General Surgery. Completed, enrolled 33 participants across 4 sites in 3 countries.

Detailed Summary

The Study investigates a new product, sFilm-FS, aimed to help controlling body fluid leakage in general surgery procedures, proposing its use as an adjunct to hemostasis and/or sealing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Slovenia, United States

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedDec 9, 2020
Enrollment StartMay 12, 2021
Primary CompletionMay 18, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.6 years ago

Interventions

sFilm-FScombination

sFilm-FS is a sterile bio-compatible bio-absorbable patch embedded with lyophilized powders of Human Fibrinogen, Human Thrombin and calcium chloride.

TACHOSIL®combination

TACHOSIL® is a fibrin sealant patch composed of an equine collagen patch coated with Human Fibrinogen and Human Thrombin.